Makya Webinar 2023
Topic: Where do we start if we don’t have any data? AI for early stage projects with Makya
Webinar Start Time: July 25, 2023 | Session 1: 10:00 – 11:00 CEST; Session 2: 17:00 – 18:00 CEST
Speakers
Quentin Perron
Chief Scientific Officier & Co-founder, Iktos
Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having a potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specialized in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.
Brian Atwood
Senior Application Scientist, Iktos
Brian Atwood is a synthetic organic chemist by training. He completed his PhD in 2018 under the direction of Chris Vanderwal at UCI. His doctoral work centered around the total synthesis of two natural products: a polychlorinated marine metabolite and a pyrrole-containing alkaloid. He then moved to UCLA to conduct postdoctoral work in the lab of Mike Jung, contributing to a variety of medicinal chemistry projects. Brian joined the Iktos team in 2020 to support US operations, applying his extensive training in synthetic planning to the development and implementation of Spaya and the Spaya API.
Matthew Medcalf
Application Scientist, Iktos
Matthew Medcalf is a synthetic organic chemist by training, completing his PhD in 2019 at Washington University in St. Louis where his thesis focused on the synthesis of cyclic depsipeptide macrocycles. Upon graduation, Matthew transitioned to medicinal chemistry as a postdoctoral research associate at Washington University School of Medicine, where he engaged in multiple projects to develop small molecule drugs towards a wide variety of disease indications. As an Application Scientist at Iktos, Matthew leverages his experience in synthetic organic chemistry and medicinal chemistry to share advances in the application of AI to accelerate drug discovery and manage research collaborations.
